Table 2 Characteristics of treatment regimens of the 30 rifampicin monoresistant tuberculosis patients included in the outcome analysis by outcome and for those with extrapulmonary tuberculosis
From: Rifampicin mono-resistant tuberculosis in France: a 2005–2010 retrospective cohort analysis
Treatment characteristic | Total patients (n = 30) | Outcome | Extrapulmonary tuberculosis° n = 10 | |||
|---|---|---|---|---|---|---|
Recovery (n = 20) | Lost to follow-up (n = 4) | Dead (n = 3) | Relapse (n = 3) | |||
Total duration of treatment | ||||||
< 6 months | 4 (13%) | 1 | 21 | 11 | 2 | |
6 to <9 months | 2 (7%) | 1 | 11 | 0 | ||
9–12 months | 13 (44%) | 92 | 2 | 21 | 7 | |
13–24 months | 11 (37%) | 102 | 1 | 1 | ||
Total FQuinolones (no AG) | 13 (43%) | 7 (35%) | 1 (25%) | 3(100%) | 2 (66%) | 6 (60%) |
1–3 months | 3 | 1 | 32 | 2 | ||
4–6 months | 1 | 0 | ||||
> 6 months | 9 | 7 | 21 | 4 | ||
Total AG (no FQuinolone) | 4 (13%) | 3 (15%) | 1 (25%) | 0 | 0 | 1 (10%) |
1–3 months | 3 | 2 | 1 | 1 | ||
> 3 months | 1 | 1 | 0 | |||
FQuinolones and AG* | 8 (26%) | 6 (30%) | 1 (25%) | 0 | 1 (33%) | 1 (10%) |
Duration of AG | ||||||
1–3 months | 6 | 53 | 11 | 0 | ||
> 3 months | 2 | 1 | 1 | 1 | ||
Duration of FQuinolones | ||||||
1–3 months | 2 | 21 | 1 | |||
4–6 months | 1 | 1 | 0 | |||
> 6 months | 5 | 41 | 11 | 0 | ||